Emma G. Wilmot

6.9k total citations · 2 hit papers
111 papers, 4.2k citations indexed

About

Emma G. Wilmot is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Emma G. Wilmot has authored 111 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Endocrinology, Diabetes and Metabolism, 37 papers in Genetics and 35 papers in Surgery. Recurrent topics in Emma G. Wilmot's work include Diabetes Management and Research (70 papers), Diabetes and associated disorders (37 papers) and Diabetes Treatment and Management (34 papers). Emma G. Wilmot is often cited by papers focused on Diabetes Management and Research (70 papers), Diabetes and associated disorders (37 papers) and Diabetes Treatment and Management (34 papers). Emma G. Wilmot collaborates with scholars based in United Kingdom, United States and France. Emma G. Wilmot's co-authors include Melanie J. Davies, Kamlesh Khunti, Thomas Yates, Trish Gorely, Stuart Biddle, Charlotte L. Edwardson, Laura J. Gray, Felix Achana, Lalantha Leelarathna and Iskandar Idris and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Emma G. Wilmot

105 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis

2012 1.3k citations Emma G. Wilmot, Melanie J. Davies et al. profile →
Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes

2022 108 citations Lalantha Leelarathna, Mark L. Evans et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emma G. Wilmot United Kingdom	29	1.7k	1.6k	1.3k	801	724	111	4.2k
Eva Corpeleijn Netherlands	42	1.6k 0.9×	979 0.6×	1.9k 1.5×	573 0.7×	480 0.7×	159	5.2k
Linda M. Delahanty United States	40	2.4k 1.4×	3.3k 2.1×	1.9k 1.4×	1.1k 1.3×	947 1.3×	115	7.6k
Gabriel Q. Shaibi United States	30	893 0.5×	1.2k 0.8×	1.8k 1.4×	673 0.8×	297 0.4×	141	3.6k
Jane E. Yardley Canada	23	1.3k 0.8×	1.8k 1.2×	361 0.3×	556 0.7×	571 0.8×	73	3.5k
Jonathan McGavock Canada	40	1.4k 0.8×	885 0.6×	1.4k 1.1×	580 0.7×	413 0.6×	148	4.5k
Paddy C. Dempsey Australia	29	2.9k 1.7×	1.1k 0.7×	1.6k 1.2×	882 1.1×	266 0.4×	82	5.0k
Jennifer R McDuffie United States	39	1.2k 0.7×	922 0.6×	1.4k 1.1×	545 0.7×	352 0.5×	89	4.2k
Danielle H. Bodicoat United Kingdom	30	1.4k 0.8×	984 0.6×	1.1k 0.9×	607 0.8×	195 0.3×	83	3.5k
Aaron S. Kelly United States	41	1.9k 1.1×	1.8k 1.2×	3.0k 2.3×	799 1.0×	1.2k 1.6×	184	7.7k
RR Wing United States	26	1.1k 0.7×	773 0.5×	1.3k 1.0×	339 0.4×	465 0.6×	34	3.4k

Countries citing papers authored by Emma G. Wilmot

Since Specialization

Citations

This map shows the geographic impact of Emma G. Wilmot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma G. Wilmot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma G. Wilmot more than expected).

Fields of papers citing papers by Emma G. Wilmot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma G. Wilmot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma G. Wilmot. The network helps show where Emma G. Wilmot may publish in the future.

Co-authorship network of co-authors of Emma G. Wilmot

This figure shows the co-authorship network connecting the top 25 collaborators of Emma G. Wilmot. A scholar is included among the top collaborators of Emma G. Wilmot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma G. Wilmot. Emma G. Wilmot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deshmukh, Harshal, Emma G. Wilmot, Pratik Choudhary, et al.. (2025). Time Below Range and Its Influence on Hypoglycemia Awareness and Severe Hypoglycemia: Insights From the Association of British Clinical Diabetologists Study. Diabetes Care. 48(3). 437–443. 7 indexed citations

Davies, Melanie J., Carl May, Shivani Misra, et al.. (2025). Using normalisation process theory to understand implementation of effective early-onset type 2 diabetes treatment and care within England: a qualitative study. BMC Health Services Research. 25(1). 422–422. 2 indexed citations

Choudhary, Pratik, et al.. (2025). The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: A narrative review of evidence and translation into clinical practice. Diabetes Obesity and Metabolism. 27(5). 2363–2376. 2 indexed citations

Wilmot, Emma G., Ketan Dhatariya, Hood Thabit, et al.. (2025). Implementation Strategies for Inpatient Continuous Glucose Monitoring-based Diabetes Management: A Systematic Review. The Journal of Clinical Endocrinology & Metabolism. 110(7). e2411–e2419. 4 indexed citations

Mader, Julia K., Ahmed Hassoun, Lutz Heinemann, et al.. (2025). Existing Knowledge Gaps in Risk Factors and Consequences of Lipohypertrophy in People Using Continuous Subcutaneous Insulin Infusion Therapy: A Systematic Review and Meta-analysis. Journal of Diabetes Science and Technology. 580929022–580929022. 1 indexed citations

Deshmukh, Harshal, Kazeem Adeleke, Emma G. Wilmot, et al.. (2024). Clinical features of type 1 diabetes in older adults and the impact of intermittently scanned continuous glucose monitoring: An Association of British Clinical Diabetologists (ABCD) study. Diabetes Obesity and Metabolism. 26(4). 1333–1339. 2 indexed citations

Forlenza, Gregory P., Daniel J. DeSalvo, Grazia Aleppo, et al.. (2024). Real-World Evidence of Omnipod ^® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology & Therapeutics. 26(8). 514–525. 36 indexed citations

Mader, Julia K., Ahmed Hassoun, Lutz Heinemann, et al.. (2024). Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis. Diabetes Technology & Therapeutics. 26(5). 351–362. 5 indexed citations

Mathieu, Chantal, Concetta Irace, Emma G. Wilmot, et al.. (2024). Minimum expectations for market authorization of continuous glucose monitoring devices in Europe—‘ eCGM ’ compliance status. Diabetes Obesity and Metabolism. 27(3). 1025–1031. 8 indexed citations

10.

Crabtree, Thomas, et al.. (2024). Patient‐reported outcomes in studies of diabetes technology: What matters. Diabetes Obesity and Metabolism. 26(S7). 59–73. 3 indexed citations

11.

Crabtree, Thomas, Lalantha Leelarathna, Peter Hammond, et al.. (2024). Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study. Diabetes Research and Clinical Practice. 209. 111597–111597. 2 indexed citations

12.

Giorgino, Francesco, Tadej Battelino, Richard M. Bergenstal, et al.. (2023). The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus. Journal of Diabetes Science and Technology. 19(2). 452–469. 5 indexed citations

13.

Field, Benjamin C. T., Yue Ruan, Jim Davies, et al.. (2023). A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID ‐19. Diabetes Obesity and Metabolism. 25(7). 2012–2022. 1 indexed citations

14.

Deshmukh, Harshal, Emma G. Wilmot, Neil Walker, et al.. (2023). Intermittently scanned continuous glucose monitoring and hypoglycaemia awareness in drivers with diabetes: Insights from the Association of British Clinical Diabetologists Nationwide audit. Diabetes Obesity and Metabolism. 26(1). 46–53. 2 indexed citations

15.

Deshmukh, Harshal, Emma G. Wilmot, Pratik Choudhary, et al.. (2022). Time in range following flash glucose monitoring: Relationship with glycaemic control, diabetes‐related distress and resource utilisation in the Association of British Clinical Diabetologists national audit. Diabetic Medicine. 39(11). e14942–e14942. 5 indexed citations

16.

Barker, Mary M., Francesco Zaccardi, Emer M. Brady, et al.. (2022). Age at diagnosis of type 2 diabetes and cardiovascular risk factor profile: A pooled analysis. World Journal of Diabetes. 13(3). 260–271. 13 indexed citations

17.

Wilmot, Emma G., Mark L. Evans, Katharine Barnard‐Kelly, et al.. (2021). Flash glucose monitoring with the FreeStyle Libre 2 compared with self-monitoring of blood glucose in suboptimally controlled type 1 diabetes: the FLASH-UK randomised controlled trial protocol. BMJ Open. 11(7). e050713–e050713. 10 indexed citations

18.

Gulsin, Gaurav S., Emer M. Brady, Anna-Marie Marsh, et al.. (2021). Clinical associations with stage B heart failure in adults with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism. 12. 2425399424–2425399424. 4 indexed citations

19.

Bain, Stephen C., Michael Feher, Miles Fisher, et al.. (2019). A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes. Diabetic Medicine. 37(2). 219–228. 3 indexed citations

20.

Wilmot, Emma G., et al.. (2019). Diabetes technology. British Journal of Diabetes. 19(2). 136–140. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact